Essential Questions for Your Oncologist About IDH-Wild-Type Glioma
Ask directly about the WHO grade (2,3, or 4) and whether molecular testing confirms this is truly IDH-wild-type, as this fundamentally determines treatment intensity and prognosis. IDH-wild-type gliomas represent a heterogeneous group requiring precise molecular characterization to separate aggressive tumors from potentially more indolent ones 1.
Critical Diagnostic Questions
Molecular Profile Confirmation
- What is the exact WHO grade (2,3, or 4)? This matters enormously—grade 2 tumors show median survival of 94.5 months versus 29.8 months for grade 3 2.
- Has TERT promoter mutation testing been completed? IDH-wild-type gliomas with TERT promoter mutations behave like molecular glioblastoma regardless of histologic grade 3.
- What is the MGMT promoter methylation status? This predicts chemotherapy response, though notably MGMT methylation may not confer survival benefit in IDH-wild-type astrocytomas as it does in glioblastoma 4.
- Were additional molecular markers tested (EGFR amplification, +7/-10, CDKN2A/B deletion)? These help distinguish true aggressive glioblastoma from potentially more indolent IDH-wild-type entities 5.
- Why is Mayo Clinic pathology review being requested? Understanding whether there's diagnostic uncertainty about grade, molecular classification, or treatment implications is crucial.
Imaging Characteristics
- Does the tumor show contrast enhancement on MRI? Non-enhancing IDH-wild-type tumors may represent different biological entities with better prognosis (median survival 3.11 years) compared to enhancing tumors (1.62 years) 5.
- Is there multifocal disease or gliomatosis pattern? These features affect surgical approach and prognosis 5.
Treatment Plan Questions
Surgical Considerations
What extent of resection is achievable, and how does this impact the treatment plan? Extent of resection is critically important—in IDH-wild-type astrocytomas, survival doubles with >50% resection and triples with >98% resection 4. This makes maximal safe resection even more important than in classical glioblastoma.
Radiation and Chemotherapy Strategy
For Grade 2 IDH-Wild-Type:
- Is the recommendation wait-and-see, radiotherapy alone (50-54 Gy), or radiotherapy followed by chemotherapy? 1
- If treatment is recommended, will it be radiotherapy followed by PCV or temozolomide chemoradiotherapy? The evidence base is limited here as this is a "heterogeneous group awaiting further subclassification" 1.
For Grade 3 IDH-Wild-Type:
- Will treatment be sequential (radiotherapy 54-60 Gy followed by temozolomide) or concurrent chemoradiotherapy? This is crucial: sequential therapy appears non-inferior to concurrent chemoradiotherapy in IDH-wild-type astrocytomas (unlike in glioblastoma), with median OS of 29.8 months for both approaches 2, 4. Sequential therapy may reduce toxicity without compromising survival.
- However, if TERT promoter mutation is present, concurrent chemoradiotherapy significantly improves survival (median OS 25.8 vs 17.2 months with RT alone) 3.
For Grade 4/Molecular Glioblastoma:
- Standard treatment is temozolomide chemoradiotherapy (54-60 Gy with concurrent and adjuvant temozolomide for 6 cycles) 1, 6.
Specific Treatment Protocol
- What is the exact radiation dose and fractionation schedule?
- If chemotherapy is recommended, will it be:
- Temozolomide (standard: 75 mg/m² daily during radiation, then 150-200 mg/m² days 1-5 of 28-day cycles) 6
- PCV (procarbazine, lomustine, vincristine)
- Sequential versus concurrent with radiation
- How many cycles of chemotherapy are planned? Standard is 6 cycles for maintenance 6.
Side Effect Questions
Radiation-Related
- What neurocognitive effects should we expect? Particularly important given the potential for longer survival in some IDH-wild-type gliomas.
- What is the risk of radiation necrosis?
- How will fatigue be managed during the 6-week radiation course?
Temozolomide-Related (if applicable)
The most critical side effects to monitor are:
- Myelosuppression (low blood counts): Weekly CBC monitoring is required during concurrent phase, then on day 22 of each maintenance cycle 6. Treatment must be held if ANC <1.5 × 10⁹/L or platelets <100 × 10⁹/L 6.
- Pneumocystis pneumonia (PCP) risk: Prophylaxis with trimethoprim-sulfamethoxazole is mandatory during concurrent chemoradiotherapy and should continue if lymphocyte counts remain low 6.
- Nausea and vomiting: Usually manageable with anti-emetics.
- Fatigue: Common and cumulative.
- Liver function abnormalities: Require monitoring.
Long-term Considerations
- What is the risk of secondary malignancies from treatment?
- How will seizures be managed if they occur?
- What supportive care will be provided for quality of life?
Prognosis and Monitoring
- What is the expected median survival based on the specific molecular profile and grade? Be direct—ranges from 17-94 months depending on grade and molecular features 2, 4.
- What defines progression, and how frequently will imaging be performed? Standard is every 3-6 months 1.
- At what point would second surgery be considered? This should always be evaluated at progression 1.
- What are the treatment options at recurrence? (temozolomide rechallenge, nitrosoureas, bevacizumab) 1.
Mayo Clinic Referral Process
- What is the timeline for pathology review?
- Will treatment be delayed pending the Mayo review?
- What specific questions are being asked of Mayo pathology?
- If the diagnosis changes based on Mayo review, how would that alter the treatment plan?
Critical Pitfall to Avoid
Do not assume all IDH-wild-type gliomas should be treated like glioblastoma. The evidence shows grade 2 tumors have dramatically better outcomes, and even grade 3 tumors may not benefit from the most aggressive concurrent chemoradiotherapy approach used in glioblastoma 2, 4. The molecular features (particularly TERT promoter mutation status) and histologic grade should guide treatment intensity, not just the IDH-wild-type status alone.